Jose-Andres C Portillo1, Isaac Schwartz1, Simona Zarini2, Reena Bapputty3, Timothy S Kern4, Rose A Gubitosi-Klug3, Robert C Murphy2, M Cecilia Subauste5, Carlos S Subauste6. 1. Division of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve University, Cleveland, Ohio, United States. 2. Department of Pharmacology, University of Colorado Denver, Aurora, Colorado, United States. 3. Department of Pediatrics, Case Western Reserve University/Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States. 4. Division of Clinical and Molecular Endocrinology, Department of Medicine, Case Western Reserve University, Cleveland, Ohio, United States. 5. Veterans Administration Medical Center, Research Service 151, Cleveland, Ohio, United States Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Case Western Reserve University, Cleveland, Ohio, United States. 6. Division of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve University, Cleveland, Ohio, United States Department of Ophthalmology and Visual Sciences, Case Western Reserve University, Cleveland, Ohio, United States Department of Pathology, Case Western Reserve University, Cleveland, Ohio, United States.
Abstract
PURPOSE: The cell surface receptor CD40 is required for the development of retinopathies induced by diabetes and ischemia/reperfusion. The purpose of this study was to identify signaling pathways by which CD40 triggers proinflammatory responses in retinal cells, since this may lead to pharmacologic targeting of these pathways as novel therapy against retinopathies. METHODS: Retinal endothelial and Müller cells were transduced with vectors that encode wild-type CD40 or CD40 with mutations in sites that recruit TNF receptor associated factors (TRAF): TRAF2,3 (ΔT2,3), TRAF6 (ΔT6), or TRAF2,3 plus TRAF6 (ΔT2,3,6). Cells also were incubated with CD40-TRAF2,3 or CD40-TRAF6 blocking peptides. We assessed intercellular adhesion molecule-1 (ICAM-1), CD40, monocyte chemoattractant protein-1 (MCP-1), VEGF, and prostaglandin E₂ (PGE₂) by fluorescence-activated cell sorting (FACS), ELISA, or mass spectrometry. Mice (B6 and CD40(-/-)) were made diabetic using streptozotocin. The MCP-1 mRNA was assessed by real-time PCR. RESULTS: The CD40-mediated ICAM-1 upregulation in endothelial and Müller cells was markedly inhibited by expression of CD40 ΔT2,3 or CD40 ΔT6. The CD40 was required for MCP-1 mRNA upregulation in the retina of diabetic mice. The CD40 stimulation of endothelial and Müller cells enhanced MCP-1 production that was markedly diminished by CD40 ΔT2,3 or CD40 ΔT6. Similar results were obtained in cells incubated with CD40-TRAF2,3 or CD40-TRAF6 blocking peptides. The CD40 ligation upregulated PGE₂ and VEGF production by Müller cells, that was inhibited by CD40 ΔT2,3 or CD40 ΔT6. All cellular responses tested were obliterated by expression of CD40 ΔT2,3,6. CONCLUSIONS: Blockade of a single CD40-TRAF pathway was sufficient to impair ICAM-1, MCP-1, PGE₂, and VEGF upregulation in retinal endothelial and/or Müller cells. Blockade of CD40-TRAF signaling may control retinopathies. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.
PURPOSE: The cell surface receptor CD40 is required for the development of retinopathies induced by diabetes and ischemia/reperfusion. The purpose of this study was to identify signaling pathways by which CD40 triggers proinflammatory responses in retinal cells, since this may lead to pharmacologic targeting of these pathways as novel therapy against retinopathies. METHODS: Retinal endothelial and Müller cells were transduced with vectors that encode wild-type CD40 or CD40 with mutations in sites that recruit TNF receptor associated factors (TRAF): TRAF2,3 (ΔT2,3), TRAF6 (ΔT6), or TRAF2,3 plus TRAF6 (ΔT2,3,6). Cells also were incubated with CD40-TRAF2,3 or CD40-TRAF6 blocking peptides. We assessed intercellular adhesion molecule-1 (ICAM-1), CD40, monocyte chemoattractant protein-1 (MCP-1), VEGF, and prostaglandin E₂ (PGE₂) by fluorescence-activated cell sorting (FACS), ELISA, or mass spectrometry. Mice (B6 and CD40(-/-)) were made diabetic using streptozotocin. The MCP-1 mRNA was assessed by real-time PCR. RESULTS: The CD40-mediated ICAM-1 upregulation in endothelial and Müller cells was markedly inhibited by expression of CD40 ΔT2,3 or CD40 ΔT6. The CD40 was required for MCP-1 mRNA upregulation in the retina of diabeticmice. The CD40 stimulation of endothelial and Müller cells enhanced MCP-1 production that was markedly diminished by CD40 ΔT2,3 or CD40 ΔT6. Similar results were obtained in cells incubated with CD40-TRAF2,3 or CD40-TRAF6 blocking peptides. The CD40 ligation upregulated PGE₂ and VEGF production by Müller cells, that was inhibited by CD40 ΔT2,3 or CD40 ΔT6. All cellular responses tested were obliterated by expression of CD40 ΔT2,3,6. CONCLUSIONS: Blockade of a single CD40-TRAF pathway was sufficient to impair ICAM-1, MCP-1, PGE₂, and VEGF upregulation in retinal endothelial and/or Müller cells. Blockade of CD40-TRAF signaling may control retinopathies. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.
Authors: Cory Ahonen; Eric Manning; Loren D Erickson; Brian O'Connor; Evan F Lind; Steven S Pullen; Marilyn R Kehry; Randolph J Noelle Journal: Nat Immunol Date: 2002-04-22 Impact factor: 25.606
Authors: F Sennlaub; F Valamanesh; A Vazquez-Tello; A M El-Asrar; D Checchin; S Brault; F Gobeil; M H Beauchamp; B Mwaikambo; Y Courtois; K Geboes; D R Varma; P Lachapelle; H Ong; F Behar-Cohen; S Chemtob Journal: Circulation Date: 2003-06-23 Impact factor: 29.690
Authors: Dimitrios T Boumpas; Richard Furie; Susan Manzi; Gabor G Illei; Daniel J Wallace; James E Balow; Akshay Vaishnaw Journal: Arthritis Rheum Date: 2003-03
Authors: Sadie K Dierschke; Allyson L Toro; William P Miller; Siddharth Sunilkumar; Michael D Dennis Journal: J Biol Chem Date: 2020-05-31 Impact factor: 5.157
Authors: Jose-Andres C Portillo; Jin-Sang Yu; Samuel Hansen; Timothy S Kern; M Cecilia Subauste; Carlos S Subauste Journal: FASEB J Date: 2021-03 Impact factor: 5.191
Authors: Jose-Andres C Portillo; Yalitza Lopez Corcino; George R Dubyak; Timothy S Kern; Shigemi Matsuyama; Carlos S Subauste Journal: Invest Ophthalmol Vis Sci Date: 2016-11-01 Impact factor: 4.799
Authors: Jose-Andres C Portillo; Yalitza Lopez Corcino; Yanling Miao; Jie Tang; Nader Sheibani; Timothy S Kern; George R Dubyak; Carlos S Subauste Journal: Diabetes Date: 2016-07-29 Impact factor: 9.461
Authors: Ivy S Samuels; Jose-Andres C Portillo; Yanling Miao; Timothy S Kern; Carlos S Subauste Journal: Vis Neurosci Date: 2017-01 Impact factor: 3.241
Authors: Nan-Sun Kim; Jacques C Mbongue; Dequina A Nicholas; Grace E Esebanmen; Juli J Unternaehrer; Anthony F Firek; William H R Langridge Journal: PLoS One Date: 2016-02-16 Impact factor: 3.240